Tred Avon Family Wealth LLC Takes Position in Pfizer Inc. $PFE

Tred Avon Family Wealth LLC bought a new position in Pfizer Inc. (NYSE:PFE) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 55,734 shares of the biopharmaceutical company’s stock, valued at approximately $1,420,000.

Several other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Pfizer by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after purchasing an additional 10,198,330 shares during the period. Geode Capital Management LLC boosted its holdings in Pfizer by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock worth $3,080,552,000 after buying an additional 1,820,634 shares during the period. Norges Bank purchased a new stake in Pfizer in the 2nd quarter worth $2,270,157,000. Charles Schwab Investment Management Inc. raised its holdings in Pfizer by 2.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock valued at $1,191,760,000 after acquiring an additional 1,135,457 shares during the period. Finally, Fisher Asset Management LLC lifted its position in shares of Pfizer by 2.0% in the second quarter. Fisher Asset Management LLC now owns 48,390,268 shares of the biopharmaceutical company’s stock valued at $1,172,980,000 after acquiring an additional 950,239 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on PFE. Bank of America cut their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a report on Wednesday, November 5th. Citigroup assumed coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price for the company. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. Finally, Scotiabank began coverage on shares of Pfizer in a report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $27.88.

Pfizer Stock Performance

Pfizer stock opened at $25.68 on Friday. The company’s 50-day moving average price is $25.35 and its 200-day moving average price is $24.99. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The company has a market cap of $146.01 billion, a PE ratio of 14.93 and a beta of 0.47. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The company had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio is 100.00%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.